Item 5.02 Departure of Directors or Certain Officers? Election of Directors?
Appointment of Certain Officers? Compensatory Arrangements of Certain Officers.
On February 6, 2023, Cyteir Therapeutics, Inc. (the "Company") announced the
promotion of the Company's Vice President of Finance, David Gaiero to Chief
Financial Officer, effective January 17, 2023. Mr. Gaiero will continue to
function as the Company's principal financial officer and principal accounting
officer.
Mr. Gaiero, age 44, has served as the Company's Vice President of Finance since
December 2020. Prior to joining Cyteir, Mr. Gaiero served in various roles at
Wave Life Sciences from 2017 to 2020, most recently serving as Interim Chief
Financial Officer and prior to that, serving as Vice President and Corporate
Controller. Prior to joining Wave, from 2015 to 2017, Mr. Gaiero served as Vice
President and Corporate Controller of OvaScience, Inc. Prior to that, Mr. Gaiero
held various positions of increasing responsibility and scope in finance and
accounting at iRobot Corporation. Mr. Gaiero began his career in public
accounting at PricewaterhouseCoopers LLP. Mr. Gaiero received a B.B.A. in
Accounting from the University of Massachusetts, Amherst, and is a Certified
Public Accountant in Massachusetts.
In connection with Mr. Gaiero's promotion, the Compensation Committee of the
Company's Board of Directors approved, effective immediately:
•
an increase in Mr. Gaiero's annual base salary to $425,000? and
•
an increase to Mr. Gaiero's target bonus opportunity to 40% of his annual base
salary.
Mr. Gaiero has entered into an employment agreement with the Company setting
forth these terms in a form consistent with the employment agreements entered
into with other executive officers of the Company. The foregoing description of
Mr. Gaiero's employment agreement does not purport to be complete and is
qualified in its entirety by reference to the full text of the agreement, which
will be filed as an exhibit to a subsequent periodic report filed with the
Securities and Exchange Commission.
There are no arrangements or understandings between Mr. Gaiero and any other
persons pursuant to which Mr. Gaiero was selected to become Chief Financial
Officer, nor are there any family relationships between Mr. Gaiero and any of
the Company's directors or other executive officers. Neither Mr. Gaiero nor any
related person of Mr. Gaiero has a direct or indirect material interest in any
existing or currently proposed transaction to which the Company is or may become
a party that would require disclosure under Item 404(a) of Regulation S-K
promulgated under the Securities Exchange Act of 1934, as amended.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
CYTEIR THERAPEUTICS, INC. 
